Literature DB >> 25439596

Clinical outcome of 500 consecutive cases undergoing Descemet's membrane endothelial keratoplasty.

Marina Rodríguez-Calvo-de-Mora1, Ruth Quilendrino1, Lisanne Ham2, Vasilios S Liarakos1, Korine van Dijk1, Lamis Baydoun1, Isabel Dapena1, Silke Oellerich3, Gerrit R J Melles4.   

Abstract

PURPOSE: To evaluate the clinical outcome of 500 consecutive cases after Descemet's membrane endothelial keratoplasty (DMEK) and the effect of technique standardization.
DESIGN: Prospective, interventional case series at a tertiary referral center. PARTICIPANTS: A total of 500 eyes of 393 patients who underwent DMEK for Fuchs' endothelial corneal dystrophy, bullous keratopathy, or previous corneal transplant failure.
METHODS: Best-corrected visual acuity (BCVA), endothelial cell density (ECD), pachymetry, and intraoperative and postoperative complications were evaluated before and 1, 3, and 6 months after DMEK. MAIN OUTCOME MEASURES: Comparison between 2 groups (group I: cases 1-250, outcome of "early surgeries" during transition to technique standardization; group II: cases 251-500, outcome of "late surgeries" after technique standardization).
RESULTS: At 6 months, 75% of eyes reached a BCVA of ≥20/25 (≥0.8), 41% of eyes achieved ≥20/20 (≥1.0), and 13% of eyes achieved ≥20/18 (≥1.2) (n=418) when excluding eyes with ocular comorbidities (n=57). When including all available eyes at 6 months (n=475), 66% of eyes reached a BCVA of ≥20/25 (≥0.8), and 36% of eyes achieved ≥20/20 (≥1.0). Mean ECD decreased by 37% (±18%) to 1600 (±490) cells/mm2 (n=447) at 6 months (P<0.001). Postoperative pachymetry averaged 525 (±46) μm compared with 667 (±92) μm preoperatively (P<0.001). None of these parameters differed among the 2 groups (P>0.05). (Partial) graft detachment presented in 79 eyes (15.8%), and 26 eyes (5.2%) required a secondary surgery within the first 6 months (re-bubbling in 15, secondary keratoplasty in 11). With technique standardization, the postoperative complication rate decreased from 23.2% to 10% (P<0.001) and the rate of secondary surgeries decreased from 6.8% to 3.6% (P=0.10).
CONCLUSIONS: In comparison with earlier endothelial keratoplasty techniques, DMEK may consistently give higher visual outcomes and faster visual rehabilitation. When used for the extended spectrum of endothelial pathologies, DMEK proved feasible with a relatively low risk of complications. Technique standardization may have contributed to a lower graft detachment rate and a relatively low secondary intervention rate. As such, DMEK may become the first choice of treatment in corneal endothelial disease.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25439596     DOI: 10.1016/j.ophtha.2014.09.004

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  42 in total

1.  "PI-less DMEK": results of Descemet's membrane endothelial keratoplasty (DMEK) without a peripheral iridotomy.

Authors:  Eitan Livny; Irit Bahar; Issac Levy; Michael Mimouni; Yoav Nahum
Journal:  Eye (Lond)       Date:  2018-12-05       Impact factor: 3.775

2.  Outcomes of Descemet membrane endothelial keratoplasty, Descemet stripping automated endothelial keratoplasty and penetrating keratoplasty from a single centre study.

Authors:  S Heinzelmann; D Böhringer; P Eberwein; T Reinhard; P Maier
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-07       Impact factor: 3.117

3.  Endothelial keratoplasty: is Descemet membrane endothelial keratoplasty the way forward? Yes.

Authors:  V S Liarakos; M Tsatsos; M Satue; G R J Melles
Journal:  Eye (Lond)       Date:  2017-04-07       Impact factor: 3.775

4.  3-Year update on the first case series of hemi-Descemet membrane endothelial keratoplasty.

Authors:  Thomas M Müller; Lamis Baydoun; Gerrit R J Melles
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-25       Impact factor: 3.117

5.  Descemet's membrane endothelial keratoplasty: surgical outcomes and endothelial cell count modelling from a UK centre.

Authors:  Mark A P Fajgenbaum; Nick Kopsachilis; Emma J Hollick
Journal:  Eye (Lond)       Date:  2018-06-19       Impact factor: 3.775

6.  Ultrahigh-resolution OCT imaging of the human cornea.

Authors:  René M Werkmeister; Sabina Sapeta; Doreen Schmidl; Gerhard Garhöfer; Gerald Schmidinger; Valentin Aranha Dos Santos; Gerold C Aschinger; Isabella Baumgartner; Niklas Pircher; Florian Schwarzhans; Anca Pantalon; Harminder Dua; Leopold Schmetterer
Journal:  Biomed Opt Express       Date:  2017-01-30       Impact factor: 3.732

7.  Outcomes of Descemet Membrane Endothelial Keratoplasty in Patients With Previous Glaucoma Surgery.

Authors:  Carolina Aravena; Fei Yu; Sophie X Deng
Journal:  Cornea       Date:  2017-03       Impact factor: 2.651

8.  Comparative analysis of biomechanical parameters of the corneas following Descemet membrane endothelial keratoplasty and contralateral healthy corneas.

Authors:  Natalya F Shilova; Yoav Nahum; Avital Adler; Irit Bahar; Boris E Malyugin; Natalia S Anisimova; Eitan Livny
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-06-11       Impact factor: 3.117

9.  Donor, Recipient, and Operative Factors Associated With Increased Endothelial Cell Loss in the Cornea Preservation Time Study.

Authors:  Jonathan H Lass; Beth Ann Benetz; Sanjay V Patel; Loretta B Szczotka-Flynn; Robert O'Brien; Allison R Ayala; Maureen G Maguire; Yassine J Daoud; Mark A Greiner; Sadeer B Hannush; W Barry Lee; Thomas F Mauger; Harry J Menegay; Mark D Mifflin; Michael B Raizman; Jennifer Rose-Nussbaumer; Robert L Schultze; Gregory A Schmidt; Alan Sugar; Mark A Terry; David D Verdier
Journal:  JAMA Ophthalmol       Date:  2019-02-01       Impact factor: 7.389

10.  Using the posterior to anterior corneal curvature radii ratio to minimize the risk of a postoperative hyperopic shift after Descemet membrane endothelial keratoplasty.

Authors:  Raphael Diener; Nicole Eter; Maged Alnawaiseh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-31       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.